India  

Covid | 'Oxford vaccine's late stage trials to start in a week in India': ICMR

Video Credit: HT Digital Content - Duration: 06:42s - Published
Covid | 'Oxford vaccine's late stage trials to start in a week in India': ICMR

Covid | 'Oxford vaccine's late stage trials to start in a week in India': ICMR

At present country has three Indian COVID-19 vaccines which are in different phases of clinical testing, said Indian Council of Medical Research (ICMR) Director General Dr Balram Bhargava on Tuesday.

Addressing a press conference in the national capital, he said, "At the present moment, we have three Indian vaccines which are in different phases of clinical testing.

The 2 vaccines- Bharat Biotech vaccine and DNA vaccine of Zydus Cadila have completed phase 1 and will begin phase 2 while third is Oxford vaccine." "Oxford vaccine, being manufactured by Serum Institute of India (SII) got approval for phase 2 and 3 clinical trials, which are starting within a week at 17 sites," he added.

Dr Bhargava, however, said that social distancing and proper hygiene are the best "vaccine" available now and even after.

"Physical Distancing, wearing a mask, proper hand hygiene are the best vaccine available at the moment and even after.

We will have to continue with these measures," he said.

India has so far recorded over 18 lakh cases and more than 38,900 deaths.


You Might Like


💡 newsR Knowledge: Other News Mentions

Balram Bhargava Indian science administrator

'5-T' strategy is to adhere to mitigate COVID-19: ICMR DG [Video]

'5-T' strategy is to adhere to mitigate COVID-19: ICMR DG

Indian Council of Medical Research Director General Balram Bhargava on September 29 said that 5-T strategy (Test, Track, Trace, Treat and Technology is to adhered to contain spread of COVID-19. "Since a large portion of the population is yet susceptible, prevention fatigue is to be avoided and 5-T strategy (Test, Track, Trace, Treat and Technology) is to be adhered," said Bhargava on Second Sero-survey.

Credit: ANI    Duration: 01:32Published
Urban slum, urban non-slum had higher SARS_CoV_2 infection prevalence than rural areas: ICMR [Video]

Urban slum, urban non-slum had higher SARS_CoV_2 infection prevalence than rural areas: ICMR

Indian Council of Medical Research Director General Balram Bhargava on September 29 said that urban slum and urban non-slum areas had higher SARS_CoV_2 infection prevalence than that of rural areas. "As per ICMR's (Indian Council of Medical Research) second sero survey report, urban slum and urban non-slum areas had higher SARS_CoV_2 infection prevalence than that of rural areas," Bhargava added.

Credit: ANI    Duration: 01:17Published

‘No vaccine for respiratory diseases has 100% efficacy’

No vaccine for respiratory diseases has a 100% efficacy and ones with a 50-100% efficacy may be approved for use against the Covid-19 pandemic, Indian Council..
IndiaTimes
Covid: 3 vaccines at clinical trial stage in India; SII’s phase 3 trial soon [Video]

Covid: 3 vaccines at clinical trial stage in India; SII’s phase 3 trial soon

Director General of the Indian Council of Medical Research (ICMR), Dr Balram Bhargava said three vaccine candidates are at different clinical trial stages in India. Covid-19 vaccine candidates being manufactured by Cadila Healthcare and Bharat Biotech have completed the first phase of the trial while the Serum Institute of India (SII) will begin with Phase 3 trial after getting the nod, Balram Bhargava, ICMR’s director general, said during the health ministry’s briefing.The Pune-based Serum Institute will conduct the Phase 3 trial on 1,500 volunteers across 14 locations, Bhargava added.

Credit: HT Digital Content    Duration: 01:19Published

Indian Council of Medical Research Indian Council of Medical Research organization

With spike of 80,472 new cases, India's COVID-19 tally crosses 62-lakh mark [Video]

With spike of 80,472 new cases, India's COVID-19 tally crosses 62-lakh mark

With a spike of 80,472 new cases, India's COVID-19 tally has crossed 62-lakh mark on September 30. Total case tally now stands at 62,25,764 including 9,40,441 active cases, 51,87,826 cured/discharged/migrated. The total number of deaths from the disease in the country mounts at 97,497. According to Indian Council of Medical Research (ICMR), A total of 7,41,96,729 samples tested for COVID, up to 29th September. Of these, 10,86,688 samples were tested yesterday.

Credit: ANI    Duration: 01:31Published

ICMR, state govts differ on Covid-19 testing numbers

The Indian Council of Medical Research (ICMR) announced on September 25 that 14,92,409 Covid tests had been conducted in the country on the previous day, a..
IndiaTimes

Serum Institute of India Serum Institute of India Indian biotechnological company, vaccine manufacturer

Serum to make extra 100 million vaccine doses

Serum Institute of India will produce up to an additional 100 million COVID-19 vaccine doses for India and low and middle-income countries in 2021.The company..
IndiaTimes

I wish government's Covid vaccine strategy was 'Mann ki Baat': Rahul Gandhi

Gandhi's tweet came after Prime Minister Narendra Modi aired his monthly 'Mann ki baat' programme on the All India Radio (AIR). Along with his comment, Gandhi..
IndiaTimes

Serum Institute CEO lauds PM Narendra Modi's COVID-19 vaccine vision day after challenging Centre on pandemic response

It is to be noted that the Serum Institute of India is all set to begin phase three trials of the Covishield Vaccine developed by AstraZeneca and Oxford..
DNA

Can Centre procure Rs 80,000 crore to buy, distribute COVID-19 vaccine across India? SII CEO Adar Poonawalla asks

On September 16, the Drugs Controller General of India (DCGI) allowed the Serum Institute of India (SII) to restart its phase two and three clinical trials for..
DNA

Phase 3 human clinical trial of Oxford vaccine begins in Pune

The phase-III human clinical trial of the Covid-19 vaccine being developed by Oxford University, and manufactured by the Serum Institute of India (SII), began at..
IndiaTimes

Cadila Healthcare Cadila Healthcare Indian multinational pharmaceutical company

Serum Institute will start phase-III trials after clearances: ICMR on COVID vaccine [Video]

Serum Institute will start phase-III trials after clearances: ICMR on COVID vaccine

Director General of Indian Council of Medical Research, Balram Bhargava on September 15 informed about the COVID-19 vaccines trial stage in India. He said, Cadila and Bharat Biotech have completed phase-I trials and Serum Institute has completed phase II-B3 trials, and will start phase-III trials after clearance. He said, "3 vaccines are at clinical trial stage in India. Cadila and Bharat Biotech have completed phase-I trials. Serum Institute has completed phase II-B3 trials, and will start phase-III trial (with 1500 patients at 14 locations) after clearances."

Credit: ANI    Duration: 01:21Published
Second national sero-survey to be completed in September first week: ICMR [Video]

Second national sero-survey to be completed in September first week: ICMR

Indian Council of Medical Research, Director General Dr. Balram Bhargava during Health Ministry's briefing on COVID-19 situation in India informed about the sero survey publication. Bhargava said, "ICMR sero survey is publication in-progress. It should appear by this week in the Indian Journal of Medical Research. It has been peer reviewed. The second national sero-survey should be completed in the first week September". On situation of COVID-19 vaccines in India, Balram Bhargava said, "Three COVID-19 vaccines are ahead in the race in India. Serum Institute's vaccine is in phase 2(B) and phase 3 trials and Bharat Biotech and Zydus Cadila's vaccines have completed phase 1 trial."

Credit: ANI    Duration: 01:49Published
Covid update: India vaccine progress; another minister infected; IMF on economy [Video]

Covid update: India vaccine progress; another minister infected; IMF on economy

From another minister in the Narendra Modi cabinet testing positive for infection, to the progress report of India's indigenously-developed vaccine candidates - here are the top news updates on the Covid-19 pandemic. Union minister of petroleum and natural gas, and steel, Dharmendra Pradhan, tested positive days after Union Home minister Amit Shah confirmed his positive diagnosis. Meanwhile, other members of the Union cabinet, like Ravi Shankar Prasad and Babul Supriyo, are quarantining themselves as a precaution. On the medical front, India's two vaccine candidates have completed phase 1 of human clinical trials. The vaccines have been developed by Bharat Biotech, ICMR and Zydus Cadila. The Jammu and Kashmir administration has decided to allow all places of worship to reopen from August 16. Earlier, the authorities had decided to cancel the annual Amarnath Yatra due to the Covid pandemic. In economic news, the International Monetary Fund has said that Covid might exacerbate the narrowing of global current account imbalances which was happening due to trade slowdown in 2019. Watch the full video for the other updates on the spread of the Sars-CoV-2 coronavirus.

Credit: HT Digital Content    Duration: 02:41Published

Bharat Biotech Bharat Biotech Indian biotechnology company and vaccine manufacturer

Bharat Biotech will involve 3,000 people for phase-III trials of COVID vaccine in UP [Video]

Bharat Biotech will involve 3,000 people for phase-III trials of COVID vaccine in UP

Speaking on phase-III trials of the COVID-19 vaccine, Uttar Pradesh Health Minister Jai Pratap Singh on September 29 said Bharat Biotech will involve 3,000 people from the state- 1,500 each from Lucknow and Gorakhpur. He said, "Phase-III trials of the COVID-19 vaccine being developed by Bharat Biotech will involve 3,000 people- 1,500 each from Lucknow and Gorakhpur."

Credit: ANI    Duration: 01:36Published

'Covaxin': Bhart Biotech to begin Phase-III trials of COVID-19 vaccine in UP from October

The Uttar Pradesh government on Thursday announced that Phase-III trials of Bharat Biotech's coronavirus (COVID-19) vaccine 'COVAXIN' will start in Lucknow and..
DNA

Tweets about this

Basant50457197

बसन्त _जी:(_0001 RT @CNNnews18: The late-stage trials of the experimental vaccine, developed with researchers from the University of Oxford, were suspended… 2 hours ago

CNNnews18

CNNNews18 The late-stage trials of the experimental vaccine, developed with researchers from the University of Oxford, were s… https://t.co/crGV1UCuVV 2 hours ago

back2thebedroom

@Back2thebedroom RT @DrGurdeepParhar: Late-stage COVID-19 vaccine trial on pause due to possible serious side effect. Here's what that means https://t.co/V… 9 hours ago

DrGurdeepParhar

Gurdeep Parhar Late-stage COVID-19 vaccine trial on pause due to possible serious side effect. Here's what that means https://t.co/VPDAidG1lS 9 hours ago

andreayd101

Andrea Doyle RT @CBCAlerts: AstraZeneca says UK clinical trials resuming for its experimental coronavirus vaccine after late-stage trials had been suspe… 11 hours ago

ivath

Ivaneth S Pernalette RT @foreignerfi: The late-stage testing will now be resumed across all trial sites in #Britain. #Oxford, AstraZeneca's #Covid19 vaccine tr… 12 hours ago

AlviseArmellini

Alvise Armellini RT @dpa_intl: Late-stage testing of the Covid-19 vaccine by AstraZeneca and Oxford University will now be resumed across all trial sites in… 12 hours ago

foreignerfi

Foreigner.fi The late-stage testing will now be resumed across all trial sites in #Britain. #Oxford, AstraZeneca's #Covid19 vac… https://t.co/n9Q3H0HDfT 13 hours ago


Related videos from verified sources

India's considerable population still vulnerable to COVID-19: ICMR's 2nd Sero Survey [Video]

India's considerable population still vulnerable to COVID-19: ICMR's 2nd Sero Survey

Indian Council of Medical Research second Sero Survey report revealed that considerable population still vulnerable to COVID-19, said Health Ministry Secretary Rajesh Bhushan on September 29. "ICMR's..

Credit: ANI     Duration: 01:27Published
UM Looking For Volunteers As Search For COVID Vaccine Enters Phase 3 Of Clinical Trials [Video]

UM Looking For Volunteers As Search For COVID Vaccine Enters Phase 3 Of Clinical Trials

CBS4's Karli Barnett spoke with Dr. Dushyantha Jayaweera, the principal investigator for Janssen’s UM site.

Credit: CBS4 Miami     Duration: 02:03Published
UM Researchers Looking For Volunteers As They Enter Phase 3 Of COVID Vaccine Clinical Trials [Video]

UM Researchers Looking For Volunteers As They Enter Phase 3 Of COVID Vaccine Clinical Trials

CBS4's Karli Barnett spoke with the researchers, who are feeling optimistic.

Credit: CBS4 Miami     Duration: 01:35Published